共 50 条
Assessment and Clinical Relevance of Non-Fasting and Postprandial Triglycerides: An Expert Panel Statement
被引:1
|作者:
Kolovou, Genovefa D.
[1
]
Mikhailidis, Dimitri P.
[2
]
Kovar, Jan
[3
]
Lairon, Dennis
[4
,5
]
Nordestgaard, Borge G.
[6
]
Ooi, Teik Chye
[7
]
Perez-Martinez, Pablo
[8
]
Bilianou, Helen
[9
]
Anagnostopoulou, Katherine
[1
]
Panotopoulos, George
[10
]
机构:
[1] Onassis Cardiac Surg Ctr, Dept Cardiol, Athens 17674, Greece
[2] UCL, Sch Med, Dept Clin Biochem, Vasc Prevent Clin, London W1N 8AA, England
[3] Inst Clin & Expt Med, Lab Atherosclerosis Res, Prague, Czech Republic
[4] INSERM, INRA, Nutriments Lipid & Prevent Malad Metab UMR1260, Bioavailabil Micronutrients U1025, F-13385 Marseille, France
[5] Univ Aix Marseille 2, F-13385 Marseille, France
[6] Univ Copenhagen, Copenhagen Univ Hosp, Fac Hlth Sci, Dept Clin Biochem,Herlev Hosp, Copenhagen, Denmark
[7] Univ Ottawa, Ottawa Hosp, Clin Res Lab, Div Endocrinol & Metab, Ottawa, ON, Canada
[8] Univ Cordoba & Ciber Fisiopatol Obesidad & Nutr, Inst Salud Carlos 3, Lipids & Atherosclerosis Unit,Hosp Univ Reina Sof, Inst Maimonides Invest Biomed Cordoba IMIBIC, Cordoba, Spain
[9] Tzanio Hosp, Dept Cardiol, Piraeus, Greece
[10] Hygeia Hosp, Dept Obes & Metab, Athens, Greece
关键词:
Postprandial triglycerides;
non-fasting triglycerides;
chylomicron remnants;
very low density lipoprotein remnants;
fat tolerance test;
cardiovascular disease;
LOW-DENSITY-LIPOPROTEIN;
CORONARY-HEART-DISEASE;
PLASMA TRIACYLGLYCEROL CONCENTRATIONS;
GENETICALLY HYPERLIPIDEMIC RABBITS;
PROSPECTIVE CARDIOVASCULAR MUNSTER;
FAMILIAL COMBINED HYPERLIPIDEMIA;
CHYLOMICRON-REMNANT CLEARANCE;
SERUM TRIGLYCERIDE;
OXIDATIVE STRESS;
APOLIPOPROTEIN-B;
D O I:
暂无
中图分类号:
R9 [药学];
学科分类号:
1007 ;
摘要:
An Expert Panel group of scientists and clinicians met to consider several aspects related to non-fasting and postprandial triglycerides (TGs) and their role as risk factors for cardiovascular disease (CVD). In this context, we review recent epidemiological studies relevant to elevated non-fasting TGs as a risk factor for CVD and provide a suggested classification of non-fasting TG concentration. Secondly, we sought to describe methodologies to evaluate postprandial TG using a fat tolerance test (FTT) in the clinic. Thirdly, we discuss the role of non-fasting lipids in the treatment of postprandial hyperlipemia. Finally, we provide a series of clinical recommendations relating to non-fasting TGs based on the consensus of the Expert Panel: 1). Elevated non-fasting TGs are a risk factor for CVD. 2). The desirable non-fasting TG concentration is <2 mmol/l (<180 mg/dl). 3). For standardized postprandial testing, a single FTT meal should be given after an 8 h fast and should consist of 75 g of fat, 25 g of carbohydrates and 10 g of protein. 4). A single TG measurement 4 h after a FTT meal provides a good evaluation of the postprandial TG response. 5). Preferably, subjects with non-fasting TG levels of 1-2 mmol/l (89-180 mg/dl) should be tested with a FTT. 6). TG concentration 2.5 mmol/l (220 mg/dl) at any time after a FTT meal should be considered as a desirable postprandial TG response. 7). A higher and undesirable postprandial TG response could be treated by aggressive lifestyle modification (including nutritional supplementation) and/or TG lowering drugs like statins, fibrates and nicotinic acid.
引用
收藏
页码:258 / 270
页数:13
相关论文